About: covid:PMC7241581

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7241581 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Clark, Nathan Allen, Arthur Barnes, Geoffrey Blumenstein, Marilyn Burnett, Allison Cuker, Adam Dager, William Deitelzweig, Steven Ellsworth, Stacy Garcia, David Kaatz, Scott Minichiello, Tracy
is schema:about of	named entity 'VTE' named entity 'enoxaparin' named entity 'COVID' named entity 'anticoagulation' named entity 'COVID' named entity 'clinical trial' named entity 'COVID' named entity 'liver function' named entity 'therapeutic purposes' named entity 'UFH' named entity 'hospital discharge' named entity 'COVID' named entity 'UFH' named entity 'Padua' named entity 'randomized controlled trials' named entity 'UFH' named entity 'clinical studies' named entity 'prophylaxis' named entity 'ST elevation myocardial infarction' named entity 'INRs' named entity 'COVID-19' named entity 'COVID-19' named entity 'anticoagulation' named entity 'COVID' named entity 'coagulopathy' named entity 'anesthesia' named entity 'Caprini' named entity 'anticoagulant' named entity 'high-risk' named entity 'pharmacologic' named entity 'evidence-based' named entity 'thrombotic events' named entity 'enoxaparin' named entity 'DOAC' named entity 'subcutaneous' named entity 'anticoagulation' named entity 'INR' named entity 'safety precautions' named entity 'pharmacologic' named entity 'heparin' named entity 'pediatric patients' named entity 'COVID' named entity 'infusion' named entity 'contraindication' named entity 'antithrombotic' named entity 'rivaroxaban' named entity 'prophylaxis' named entity 'Anticoagulation' named entity 'UFH' named entity 'prophylactic' named entity 'COVID' named entity 'renal function' named entity 'anticoagulation' named entity 'antivirals' named entity 'prophylaxis' named entity 'COVID' named entity 'enoxaparin' named entity 'prophylactic' named entity 'management decisions' named entity 'VTE' named entity 'COVID' named entity 'high-risk' named entity 'anticoagulation' named entity 'non-pregnant' named entity 'ACOG' named entity 'betrixaban' named entity 'LMWH' named entity 'anticoagulant therapy' named entity 'ICU' named entity 'expert opinion' named entity 'anticoagulation' named entity 'VTE' named entity 'LMWH' named entity 'anticoagulation' named entity 'VTE' named entity 'Anticoagulation' named entity 'COVID-19' named entity 'follow-up' named entity 'evidence-based' named entity 'clinical trial' named entity 'critically ill patients' named entity 'drug-drug interactions' named entity 'risks and benefits' named entity 'anticoagulation' named entity 'prophylaxis' named entity 'Anticoagulation' named entity 'drug-drug interactions' named entity 'drug-drug interactions'

Attributes

Values

Creator

Clark, Nathan
Allen, Arthur
Barnes, Geoffrey
Blumenstein, Marilyn
Burnett, Allison
Cuker, Adam
Dager, William
Deitelzweig, Steven
Ellsworth, Stacy
Garcia, David
Kaatz, Scott
Minichiello, Tracy

is schema:about of

named entity 'VTE'
named entity 'enoxaparin'
named entity 'COVID'
named entity 'anticoagulation'
named entity 'COVID'
named entity 'clinical trial'
named entity 'COVID'
named entity 'liver function'
named entity 'therapeutic purposes'
named entity 'UFH'
named entity 'hospital discharge'
named entity 'COVID'
named entity 'UFH'
named entity 'Padua'
named entity 'randomized controlled trials'
named entity 'UFH'
named entity 'clinical studies'
named entity 'prophylaxis'
named entity 'ST elevation myocardial infarction'
named entity 'INRs'
named entity 'COVID-19'
named entity 'COVID-19'
named entity 'anticoagulation'
named entity 'COVID'
named entity 'coagulopathy'
named entity 'anesthesia'
named entity 'Caprini'
named entity 'anticoagulant'
named entity 'high-risk'
named entity 'pharmacologic'
named entity 'evidence-based'
named entity 'thrombotic events'
named entity 'enoxaparin'
named entity 'DOAC'
named entity 'subcutaneous'
named entity 'anticoagulation'
named entity 'INR'
named entity 'safety precautions'
named entity 'pharmacologic'
named entity 'heparin'
named entity 'pediatric patients'
named entity 'COVID'
named entity 'infusion'
named entity 'contraindication'
named entity 'antithrombotic'
named entity 'rivaroxaban'
named entity 'prophylaxis'
named entity 'Anticoagulation'
named entity 'UFH'
named entity 'prophylactic'
named entity 'COVID'
named entity 'renal function'
named entity 'anticoagulation'
named entity 'antivirals'
named entity 'prophylaxis'
named entity 'COVID'
named entity 'enoxaparin'
named entity 'prophylactic'
named entity 'management decisions'
named entity 'VTE'
named entity 'COVID'
named entity 'high-risk'
named entity 'anticoagulation'
named entity 'non-pregnant'
named entity 'ACOG'
named entity 'betrixaban'
named entity 'LMWH'
named entity 'anticoagulant therapy'
named entity 'ICU'
named entity 'expert opinion'
named entity 'anticoagulation'
named entity 'VTE'
named entity 'LMWH'
named entity 'anticoagulation'
named entity 'VTE'
named entity 'Anticoagulation'
named entity 'COVID-19'
named entity 'follow-up'
named entity 'evidence-based'
named entity 'clinical trial'
named entity 'critically ill patients'
named entity 'drug-drug interactions'
named entity 'risks and benefits'
named entity 'anticoagulation'
named entity 'prophylaxis'
named entity 'Anticoagulation'
named entity 'drug-drug interactions'
named entity 'drug-drug interactions'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software